Bone-targeting agents in prostate cancer

Daniel L. Suzman, Sosipatros A. Boikos, Michael A Carducci

Research output: Contribution to journalArticle

Abstract

Bone metastases are present in the vast majority of men with advanced prostate cancer, representing the main cause for morbidity and mortality. Recurrent or metastatic disease is managed initially with androgen deprivation but the majority of the patients eventually will progress to castration-resistant prostate cancer, with patients developing bone metastases in most of the cases. Survival and growth of the metastatic prostate cancer cells is dependent on a complex microenvironment (onco-niche) that includes the osteoblasts, the osteoclasts, the endothelium, and the stroma. This review summarizes agents that target the pathways involved in this complex interaction between prostate cancer and bone microenvironment and aim to transform lethal metastatic prostate cancer into a chronic disease.

Original languageEnglish (US)
Pages (from-to)619-628
Number of pages10
JournalCancer and Metastasis Reviews
Volume33
Issue number2-3
DOIs
StatePublished - 2014

Fingerprint

Prostatic Neoplasms
Bone and Bones
Neoplasm Metastasis
Bone Neoplasms
Tumor Microenvironment
Castration
Osteoclasts
Osteoblasts
Androgens
Endothelium
Chronic Disease
Morbidity
Survival
Mortality
Growth

Keywords

  • Bone metastases
  • Bone-targeting agents
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Bone-targeting agents in prostate cancer. / Suzman, Daniel L.; Boikos, Sosipatros A.; Carducci, Michael A.

In: Cancer and Metastasis Reviews, Vol. 33, No. 2-3, 2014, p. 619-628.

Research output: Contribution to journalArticle

Suzman, Daniel L. ; Boikos, Sosipatros A. ; Carducci, Michael A. / Bone-targeting agents in prostate cancer. In: Cancer and Metastasis Reviews. 2014 ; Vol. 33, No. 2-3. pp. 619-628.
@article{c56d450ae8d946a99737b2aab0d9f89c,
title = "Bone-targeting agents in prostate cancer",
abstract = "Bone metastases are present in the vast majority of men with advanced prostate cancer, representing the main cause for morbidity and mortality. Recurrent or metastatic disease is managed initially with androgen deprivation but the majority of the patients eventually will progress to castration-resistant prostate cancer, with patients developing bone metastases in most of the cases. Survival and growth of the metastatic prostate cancer cells is dependent on a complex microenvironment (onco-niche) that includes the osteoblasts, the osteoclasts, the endothelium, and the stroma. This review summarizes agents that target the pathways involved in this complex interaction between prostate cancer and bone microenvironment and aim to transform lethal metastatic prostate cancer into a chronic disease.",
keywords = "Bone metastases, Bone-targeting agents, Prostate cancer",
author = "Suzman, {Daniel L.} and Boikos, {Sosipatros A.} and Carducci, {Michael A}",
year = "2014",
doi = "10.1007/s10555-013-9480-2",
language = "English (US)",
volume = "33",
pages = "619--628",
journal = "Cancer and Metastasis Reviews",
issn = "0167-7659",
publisher = "Springer Netherlands",
number = "2-3",

}

TY - JOUR

T1 - Bone-targeting agents in prostate cancer

AU - Suzman, Daniel L.

AU - Boikos, Sosipatros A.

AU - Carducci, Michael A

PY - 2014

Y1 - 2014

N2 - Bone metastases are present in the vast majority of men with advanced prostate cancer, representing the main cause for morbidity and mortality. Recurrent or metastatic disease is managed initially with androgen deprivation but the majority of the patients eventually will progress to castration-resistant prostate cancer, with patients developing bone metastases in most of the cases. Survival and growth of the metastatic prostate cancer cells is dependent on a complex microenvironment (onco-niche) that includes the osteoblasts, the osteoclasts, the endothelium, and the stroma. This review summarizes agents that target the pathways involved in this complex interaction between prostate cancer and bone microenvironment and aim to transform lethal metastatic prostate cancer into a chronic disease.

AB - Bone metastases are present in the vast majority of men with advanced prostate cancer, representing the main cause for morbidity and mortality. Recurrent or metastatic disease is managed initially with androgen deprivation but the majority of the patients eventually will progress to castration-resistant prostate cancer, with patients developing bone metastases in most of the cases. Survival and growth of the metastatic prostate cancer cells is dependent on a complex microenvironment (onco-niche) that includes the osteoblasts, the osteoclasts, the endothelium, and the stroma. This review summarizes agents that target the pathways involved in this complex interaction between prostate cancer and bone microenvironment and aim to transform lethal metastatic prostate cancer into a chronic disease.

KW - Bone metastases

KW - Bone-targeting agents

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84905102378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905102378&partnerID=8YFLogxK

U2 - 10.1007/s10555-013-9480-2

DO - 10.1007/s10555-013-9480-2

M3 - Article

C2 - 24398856

AN - SCOPUS:84905102378

VL - 33

SP - 619

EP - 628

JO - Cancer and Metastasis Reviews

JF - Cancer and Metastasis Reviews

SN - 0167-7659

IS - 2-3

ER -